1 Min Read
Sept 6 (Reuters) - Biocon Ltd
* Says JDRF supports biocon study of novel, fast-acting oral insulin tregopil for type 1 diabetes treatment Source text - bit.ly/2wEFaOf Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.